Picture this: a group of researchers in Greece, delving into the world of weed and its potential medicinal benefits. But this wasn’t just any ordinary study – this one involved a vaporized weed formula with a whopping 13% CBD and 9% THC. And the focus? Multiple sclerosis.
That’s right, folks. The researchers were interested in how this potent weed formula would affect 69 patients with multiple sclerosis. These patients had a range of symptoms, from muscle spasticity to bladder dysfunction to disability progressions. And the researchers were determined to see if this vaporized weed could bring them some relief.
But before they could get to the good stuff, the researchers had to establish a baseline. They analyzed the patients’ symptoms and levels of disability at the start of the study. And then, they waited. Three months went by, and then six. And finally, it was time to see the results.
And boy, were they impressive. According to the researchers, “significant improvement was observed across all outcome assessments” after the patients were given the vaporized weed. That’s right – all of the patients showed improvement in their symptoms and levels of disability. Talk about a game-changer.
But let’s not get ahead of ourselves. This study is just one of many in the ever-growing field of medical marijuana research. And while the results are promising, there’s still a lot to learn about the potential benefits and risks of using weed as a form of treatment.
But for now, let’s raise a joint to this groundbreaking study out of Greece. Who knows what other wonders the world of weed has in store for us?
